Showing results (441-450 of 532) with videos related to
Sort By:
Pageof 54
Plos One|October 5, 2018
Profiling of circulating exosomal miRNAs in patients with Waldenström MacroglobulinemiaJuliette M Bouyssou, Chia-Jen Liu, Mark Bustoros, et al.The Journal of Clinical Investigation|December 10, 1999
Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injuryF Amersi, R Buelow, H Kato, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.Blood|February 19, 2017
Prognostic role of circulating exosomal miRNAs in multiple myelomaSalomon Manier, Chia-Jen Liu, Hervé Avet-Loiseau, et al.Leukemia|February 10, 2016
Targeting vasculogenesis to prevent progression in multiple myelomaM Moschetta, Y Mishima, Y Kawano, et al.Leukemia|June 22, 2018
Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow nicheShokichi Tsukamoto, Marianne B Løvendorf, Jihye Park, et al.European Journal of Haematology|March 12, 2008
Clinical relevance of soluble HLA class I molecules in Waldenstrom MacroglobulinemiaAnne-Sophie Moreau, Yasmine Sebti, Alain Duhamel, et al.Leukemia|July 4, 2015
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemiaI M Ghobrial, R Redd, P Armand, et al.Blood|November 19, 2011
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironmentAbdel Kareem Azab, Phong Quang, Feda Azab, et al.Cell Reports|September 30, 2014
SDF-1 inhibition targets the bone marrow niche for cancer therapyAldo M Roccaro, Antonio Sacco, Werner G Purschke, et al.Pageof 54